Mizuho Securities USA LLC Acquires 196,380 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mizuho Securities USA LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1,397.9% in the third quarter, Holdings Channel reports. The fund owned 210,428 shares of the medical research company’s stock after purchasing an additional 196,380 shares during the quarter. Mizuho Securities USA LLC’s holdings in IQVIA were worth $49,865,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA in the third quarter worth approximately $28,000. Versant Capital Management Inc grew its position in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA in the second quarter worth $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA during the second quarter worth $29,000. 89.62% of the stock is owned by institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Evercore ISI lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Argus raised shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. Finally, UBS Group boosted their target price on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Trading Down 5.1 %

Shares of NYSE:IQV opened at $192.63 on Friday. The stock has a market cap of $34.96 billion, a price-to-earnings ratio of 25.28, a PEG ratio of 2.17 and a beta of 1.51. The business has a 50-day moving average price of $226.95 and a 200-day moving average price of $228.29. IQVIA Holdings Inc. has a 52-week low of $189.63 and a 52-week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.